Neurocrine Biosciences Shows Market Leadership With Jump To 83 RS Rating

When considering what names to put on your watch list, focus on stocks with an 80 or higher RS Rating. Neurocrine Biosciences (NBIX) just cleared that benchmark with an upgrade from 80 to 83.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This proprietary rating measures technical performance by showing how a stock’s price movement over the last 52 weeks compares to that of the other stocks in our database.

Over 100 years of market history shows that the market’s biggest winners tend to have an RS Rating north of 80 as they launch their biggest runs.

Looking For The Best Stocks To Buy And Watch? Start Here

Neurocrine Biosciences is working on a cup without handle with a 108.11 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.

While earnings-per-share growth fell in the company’s most recently reported quarter from 0% to -96%, the top line rose 26%, up from 15% in the previous report. Keep an eye out for the company’s next round of numbers on or around May 5.

Neurocrine Biosciences earns the No. 15 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls (AMPH) and Regeneron Pharmaceutical (REGN) are also among the group’s highest-rated stocks.


Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Find Top Stocks Near A Buy Point With IBD Leaderboard

Most Related Links :
honestcolumnist Governmental News Finance News

Source link

Back to top button